Humacyte (HUMA)
NASDAQ:HUMA
Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.71
-$0.19(-4.01%)
At close: 4:00 PM EST
$0.71
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.55 - $2.93
Previous CloseN/A
Volume1.64M
Average Volume (3M)5.88M
Market Cap
$233.12M
Enterprise Value$193.76M
Total Cash (Recent Filing)$48.54M
Total Debt (Recent Filing)$65.90M
Price to Earnings (P/E)―
Beta2.89
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding222,019,100
10 Day Avg. Volume8,206,850
30 Day Avg. Volume5,880,199
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue96.11
Enterprise Value/Gross Profit-12.84
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$2.27Price Target Upside219.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$11.18M
Bulls Say, Bears Say
Bulls Say
Clinical Trial And Regulatory PathwayAn upcoming interim analysis from a late-stage dialysis trial could produce compelling data to support a regulatory filing and thereby open a substantially larger dialysis market for the vascular graft technology.
Institutional And Military Channel ExpansionInclusion on the military electronic purchasing catalog and endorsements from military trauma surgeons create an institutional pathway that could expand access across military treatment facilities and Veterans Affairs hospitals and accelerate civilian adoption through accumulated clinical experience.
Pricing-driven AdoptionLowering Symvess's average selling price has improved surgeon adoption, indicating that targeted pricing changes could materially drive broader hospital uptake and volume growth.
Bears Say
Dilutive Financing And Increased Share CountAdditional financing completed at a discounted price and issuance of shares related to prior financing arrangements increase dilution risk and may limit near-term share price upside.
Launch Execution And Cash Burn PressureInitial U.S. launch results combined with a high cash burn rate raise short-term financial pressure and could constrain operational flexibility until commercial traction improves.
Weak Initial Sales PerformanceReported product sales well below expectations underscore early commercialization challenges that could continue to pressure near-term revenue and investor confidence.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.93 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $233.12M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 17, 2026 which is in 83 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.026.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.11.
How many shares outstanding does Humacyte have?
Humacyte has 222,019,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 24.176%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.27 (219.95% Upside)
$2.27 (219.95% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $59.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.25%
12-Months-Change
Fundamentals
Return on Equity
-2781.56%
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
HUMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted tangible commercial momentum (Symvess unit and revenue growth), strengthened commercial leadership, international regulatory progress (Israel MAA accepted), strategic government interest (DoD funding), and important near-term clinical catalysts (V012 interim results due June 11 and CTEV Phase I/II planned H2 2026). These operational and pipeline advances were balanced against financial headwinds in the quarter: a swing to a $17.6M net loss driven largely by reduced noncash other income, a large inventory reserve that inflated COGS, increased R&D spend for CTEV manufacturing, and modest absolute product revenue despite high percentage growth. The company has taken actions (restructuring, senior hires, targeted commercialization) to address uptake and cost structure and reported a cash position of $48.9M. Overall, progress on product, pipeline, and commercialization initiatives combined with cost-saving actions and an upcoming trial readout lead to a cautiously optimistic view of the company’s near-term prospects, tempered by the recent negative impact on profitability and remaining timing uncertainties around regulatory and procurement milestones.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$2.27
▲(219.95% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.88% Insiders
5.22% Mutual Funds
6.35% Other Institutional Investors
70.70% Public Companies and
Individual Investors